BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36470330)

  • 1. Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models.
    Kostka L; Kotrchová L; Randárová E; Ferreira CA; Malátová I; Lee HJ; Olson AP; Engle JW; Kovář M; Cai W; Šírová M; Etrych T
    J Control Release; 2023 Jan; 353():549-562. PubMed ID: 36470330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymer nanomedicines based on micelle-forming amphiphilic or water-soluble polymer-doxorubicin conjugates: Comparative study of in vitro and in vivo properties related to the polymer carrier structure, composition, and hydrodynamic properties.
    Braunová A; Chytil P; Laga R; Šírová M; Machová D; Parnica J; Říhová B; Janoušková O; Etrych T
    J Control Release; 2020 May; 321():718-733. PubMed ID: 32142741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
    Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
    J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tumor-targeted polymer theranostics platform for positron emission tomography and fluorescence imaging.
    Koziolová E; Goel S; Chytil P; Janoušková O; Barnhart TE; Cai W; Etrych T
    Nanoscale; 2017 Aug; 9(30):10906-10918. PubMed ID: 28731080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
    Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
    J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization.
    Randárová E; Nakamura H; Islam R; Studenovský M; Mamoru H; Fang J; Chytil P; Etrych T
    Acta Biomater; 2020 Apr; 106():256-266. PubMed ID: 32058082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
    Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
    J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bloodstream Stability Predetermines the Antitumor Efficacy of Micellar Polymer-Doxorubicin Drug Conjugates with pH-Triggered Drug Release.
    Chytil P; Šírová M; Kudláčová J; Říhová B; Ulbrich K; Etrych T
    Mol Pharm; 2018 Sep; 15(9):3654-3663. PubMed ID: 29543465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.
    Braunová A; Kostka L; Sivák L; Cuchalová L; Hvězdová Z; Laga R; Filippov S; Černoch P; Pechar M; Janoušková O; Šírová M; Etrych T
    J Control Release; 2017 Jan; 245():41-51. PubMed ID: 27871991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
    Etrych T; Subr V; Strohalm J; Sírová M; Ríhová B; Ulbrich K
    J Control Release; 2012 Dec; 164(3):346-54. PubMed ID: 22759979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(2-ethyl-2-oxazoline) conjugates with doxorubicin for cancer therapy: In vitro and in vivo evaluation and direct comparison to poly[N-(2-hydroxypropyl)methacrylamide] analogues.
    Sedlacek O; Monnery BD; Mattova J; Kucka J; Panek J; Janouskova O; Hocherl A; Verbraeken B; Vergaelen M; Zadinova M; Hoogenboom R; Hruby M
    Biomaterials; 2017 Nov; 146():1-12. PubMed ID: 28892751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel star HPMA-based polymer conjugates for passive targeting to solid tumors.
    Etrych T; Strohalm J; Chytil P; Říhová B; Ulbrich K
    J Drug Target; 2011 Dec; 19(10):874-89. PubMed ID: 21978286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release: synthesis and characterization of distribution and tumor accumulation in mice by noninvasive multispectral optical imaging.
    Hoffmann S; Vystrčilová L; Ulbrich K; Etrych T; Caysa H; Mueller T; Mäder K
    Biomacromolecules; 2012 Mar; 13(3):652-63. PubMed ID: 22263698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
    Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
    J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone nanomedicines with optimized drug release kinetics tailored for treatment of site-specific rheumatic musculoskeletal diseases.
    Libánská A; Randárová E; Rubanová D; Skoroplyas S; Bryja J; Kubala L; Konefal R; Navrátilová A; Cerezo LA; Šenolt L; Etrych T
    Int J Pharm; 2024 Apr; 654():123979. PubMed ID: 38458405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
    Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
    Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
    Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
    Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chain-extension in hyperbranched polymers alters tissue distribution and cytotoxicity profiles in orthotopic models of triple negative breast cancers.
    Moloney C; Mehradnia F; Cavanagh RJ; Ibrahim A; Pearce AK; Ritchie AA; Clarke P; Rahman R; Grabowska AM; Alexander C
    Biomater Sci; 2023 Sep; 11(19):6545-6560. PubMed ID: 37593851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymer nanomedicines with enzymatically triggered activation: A comparative study of in vitro and in vivo anti-cancer efficacy related to the spacer structure.
    Pechar M; Pola R; Studenovský M; Bláhová M; Grosmanová E; Dydowiczová A; Filipová M; Islam R; Gao S; Fang J; Etrych T
    Nanomedicine; 2022 Nov; 46():102597. PubMed ID: 36064033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging.
    Etrych T; Daumová L; Pokorná E; Tušková D; Lidický O; Kolářová V; Pankrác J; Šefc L; Chytil P; Klener P
    J Control Release; 2018 Nov; 289():44-55. PubMed ID: 30248447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.